Clinical trials: ctDNA Monitoring
Colorectal Cancer, MRD
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer.
- Conditions
- Colorectal Cancer, MRD, ctDNA
- Trial name
- NCT07254156
- Testing
- MRD detection
- Where
- China
- Volunteers
- 229 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer, Advanced Cancer
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- MAP-01 (NCT05802420)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer.
- Trial name
- REMNANT (NCT05375370)
- Testing
- circulating tumor DNA dosage
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Gastric Cancer
Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
This study aims to evaluate the clinical value of circulating tumor DNA (ctDNA) as a minimally invasive biomarker for monitoring treatment response and guiding systemic therapy in patients with gastric or gastroesophageal…
- Trial name
- NCT07517107
- Testing
- Circulating Tumor DNA (ctDNA) Analysis, Standard Systemic Therapy for Gastric Cancer
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
The purpose of this prospective biospecimen collection study is to evaluate the feasibility of measuring circulating tumor DNA (ctDNA) in subjects with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy…
- Trial name
- NCT05630131
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Cancer
ctDNA-MRD Monitoring After Resection in Gastric Cancer
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and…
- Trial name
- MRD-GC (NCT06893133)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University
Breast Cancer
CIrCuLAting Dna ESr1 Gene Mutations Analysis
The estrogen-dependent nature of breast cancer was first reported in 1896 with the publication of George Beatson's observations on the regression of breast cancer following oophorectomy.
- Trial name
- CICLADES (NCT03318263)
- Testing
- next-generation sequencing (NGS)
- Where
- 10 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut de Cancérologie de Lorraine
Diffuse Large B Cell Lymphoma
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who relapse within 12 months of chemotherapy usually undergo salvage therapies, followed by autologous transplant with a low success rate.
- Trial name
- NCT03311958
- Testing
- Nivolumab, IV, 240 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Non-Small Cell Lung Cancer
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden. In this study, PEAC (Personalized Analysis of Cancer) technology was performed to detect the driver gene mutations from plasma…
- Trial name
- EVOLUTION (NCT04238130)
- Testing
- Perioperative ctDNA Dynamic Monitoring
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Stage III Colorectal Cancer
Use of ctDNA for Monitoring of Stage III Colorectal Cancer
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
- Trial name
- NCT02842203
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Pittsburgh
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Gastric Cancer, ctDNA
Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description
This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy
- Trial name
- NCT05029869
- Testing
- ctDNA
- Where
- Vietnam
- Volunteers
- 100 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Diffuse Large B Cell Lymphoma
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA…
- Trial name
- RT-CAR (NCT05675982)
- Testing
- CAR-T cells monitoring
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Henri Becquerel
Recurrent or Metastatic Breast Cancer
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
This was a prospective, single-center clinical study. The study was designed to investigate the relationship between plasma HER2 amplification or specific mutations abundance and clinical response in patients with recurrent or…
- Trial name
- NCT03947736
- Testing
- cfDNA was detected by dPCR
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Primary Central Nervous System Lymphoma
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition.
- Trial name
- NCT07851363
- Testing
- HD-MTX-based chemotherapy, BTK inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiaohui Ren
Minimal Residual Disease, Esophageal Squamous Cell Carcinoma
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection.
- Trial name
- NCT05900583
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Provincial People's Hospital
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
This retrospective-prospective observational cohort study aims to evaluate peripheral blood plasma circulating tumor DNA (ctDNA) dynamics in pediatric acute leukemia and compare ctDNA results with concurrent bone marrow…
- Trial name
- NCT07751588
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
The goal of this adaptive, interventional study is to assess the efficacy and safety of osimertinib-based adaptive treatment based on ctDNA dynamic monitoring in locally advanced or metastatic EGFRm NSCLC participants with ctDNA…
- Trial name
- NCT07058519
- Testing
- Osimertinib-based adaptive treatment, Osimertinib 80 MG
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital